2020 activities summary - ESWI Organization
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
2020 activities summary
The European Scientific Working group on Influenza
The European (ESWI) is a group of key scientific experts in influenza
who have joined forces to reduce the burden
of influenza in Europe:
Scientific ■ Ted van Essen, Amersfoort, The Netherlands
Gülsah Gabriel, Heinrich-Pette-Institute, Leibniz Institute for Experimental Virology,
Working group
■
Hamburg, Germany
■ Terho Heikkinen, University of Turku, Finland
Susanne Herold, University of Giessen Lung Centre, Germany
on Influenza
■
■ George Kassianos, GP and National Immunisation Lead Royal College of General
Practitioners, UK
■ Edward C. Hutchinson, University of Glasgow, UK
■ Colin Russell, University of Amsterdam, The Netherlands
■ Peter Openshaw, Imperial College London, UK
■ Ab Osterhaus, Research Center for Emerging Infections and Zoonoses Hannover,
Germany
■ Roman Prymula, Military Hospital of Hradec Kralove, Czech Republic
■ Sylvie van der Werf, Institut Pasteur, Paris, France
■ Marco Goeijenbier, Erasmus MC, Rotterdam, The Netherlands
To realize its
objective, ESWI has
established structural euregha
European Regional and Local Health Authorities European Academy of Paediatrics
partnerships with
U.E.M.S - Section of Paediatrics - European Union of Medical Specialists
influenza stakeholder
organisations:
PGEU GPUE
Pharmaceutical Group of the European Union
Groupement Pharmaceutique de L’Union Européenne
EUROPE
CORONAVIRUS, FLU AND RSV COLLIDING IN THE FALL In the middle of the COVID-19 pandemic and when the world was dealing with the unrelenting daily spread of the novel coronavirus ESWI wanted to look further down the road. In June 2020 already we wanted to warn the world that when flu season comes, there is a possibility that the world would be dealing with two respiratory viruses at the same time – flu and COVID-19. ESWI organised 4 LIVE webinars.
1. INFLUENZA AND RSV IN A COVID-19 WORLD
THURSDAY 11 JUNE 2020 16:00-18:00 CET CONCLUSIONS
It is very difficult to predict what’s going to happen in the coming months. It’s generally
accepted that a second wave of COVID-19 is extremely likely, as is the recurrence of
Influenza, RSV and COVID-19: similarities and differences seasonal flu. But no one can predict whether the combination of both viruses is going
Arnold Monto, University of Michigan , USA to be less or more severe than the appearance of just one of them.
Influenza and COVID-19 together may be less severe due to the COVID-19 mitigation
measures, including the TTTQ (Test, Track & Trace, and Quarantine) measures
Epidemiology: what if COVID-19 strikes in the flu season? implemented in many countries, which may lessen the influence of influenza too.
Moreover, the appearance of one virus may limit the appearance of the other, due to
Colin Russell, University of Amsterdam , The Netherlands
the phenomenon of viral interference.
On the other hand, the effects of influenza and COVID-19 together may be more
Challenges in serology for COVID-19 severe due to the appearance of both of them at the same time.
Linfa Wang, Duke-NUS Medical School , Singapore
RECOMMENDATIONS
1. Be prepared for the reappearance of both flu and COVID-19 in the fall of 2020.
Diagnoses for influenza, RSV and COVID-19
and consequences 2. Increase flu vaccination coverage. This is particularly crucial for the high risk groups
and for healthcare workers. Minimum coverage for these groups is generally
Marco Goeijenbier, Erasmus MC , The Netherlands accepted to be 70%, a level that has not yet been reached in most countries of the
world.
3. Be prepared to stock and use the flu antivirals available.
4. Continue extensive surveillance and testing for flu, other respiratory viruses such as
RSV, and COVID-19.
2. CLINICAL MANIFESTATIONS OF COVID-19, INFLUENZA AND RSV
THURSDAY 18 JUNE 2020 16:00-18:00 CET CONCLUSIONS
There is a large overlap in the clinical symptoms of COVID-19, influenza and RSV. Good
laboratory diagnosis is therefore essential, especially as the three infections may coincide,
Clinical signs and symptoms: overlap and differences influencing their respective severities in a positive or negative way. Thankfully, more than 80% of
Barbara Rath, Vienna Vaccine Safety Initiative , Germany all people infected with COVID-19 have relatively mild symptoms.
Loss of taste or smell, and severe lung pathology, are seen in both flu and COVID-19 infections,
although abnormal coagulation in the lungs tends to be a typical symptom of COVID-19,
Risk groups: overlap and differences especially among severely infected or ventilated patients.
Generally there is a large overlap in the risk groups for influenza and COVID-19. Interestingly
Daniel Feikin, World Health Organisation , Switzerland though, children and pregnant women, who are greatly at risk for influenza, seem to be at much
less risk for COVID-19. Insufficient data is available for RSV in this respect.
As regards therapeutic interventions, treatment of the symptoms is essential at different levels,
Clinical guidance and symptomatic treatment
such as in the front line, nursing homes, hospitals, and ICUs. No specific antivirals have yet
Peter Openshaw, Imperial College London , been developed. There have been quite high expectations for certain repurposed drugs but
United Kingdom the results are unclear. Also, most potential COVID-19 antivirals have not been tested in very
early stage patients. Many studies are being carried out amongst Biological Response Modifiers
with varying degrees of potential. Dexamethasone might be the most promising with a 30%
reduction in clinical symptoms.
Co-infections: possible scenario’s
Bruno Lina, Université de Lyon , France RECOMMENDATIONS
1. Implement and comply with non-pharmaceutical interventions such as lockdowns,
social distancing, and face masks.
2. Very early intervention is key. Earlier implementation of lockdowns could have resulted in
significantly fewer casualties.
3. Test, Track & Trace, and Quarantine (TTTQ) all infected patients and their contacts.
4. Use smart apps wherever possible to identify people who might be infected.
5. Ensure first line treatment of patients by GPs.
6. Prepare hospitals and ICUs using the latest data.
7. Promote more extensive flu vaccination and flu antiviral storage.
3. INTERVENTION STRATEGIES FOR COVID-19, INFLUENZA AND RSV
TUESDAY 23 JUNE 2020 16:00-18:00 CET CONCLUSIONS
It’s clear that public health and social measures can stop ongoing individual chains
of transmission and prevent new outbreaks of COVID-19. A combined strategy
Current strategies of early lockdown with Test, Track & Trace, and Quarantine (TTTQ) measures is
Ab Osterhaus, RIZ, Hannover , Germany important to limit the next wave of outbreaks. Surveillance and testing capacity for
COVID-19, flu and RSV is crucial, along with the detection of the viruses and, in the
case of COVID-19, the antibodies.
Testing and testing consequences Therapeutic strategies currently being investigated have yielded their first
encouraging successes, but more studies are needed. Various repurposed antivirals
Chantal Reusken, RIVM , The Netherlands and other anti-infectives such as anti-HIV, remdesivir and hydroxychloroquine show
mixed potential. Biological Response Modifiers such as dexamethasone and others
are being studied, as are polyclonal and monoclonal antibodies.
Influenza vaccination during COVID-19
Florian Krammer, Icahn School of Medicine , USA
RECOMMENDATIONS
In the absence of a COVID-19 vaccine, and with limited therapeutic options, it
Antivirals & Biological Response Modifiers becomes even more essential to:
Mike Ison, Northwestern University, USA 1. Thoroughly prepare flu vaccination campaigns for the coming season.
2. Increase the stocks and usage of influenza antivirals.
4. CORNERSTONES OF PANDEMIC PREPAREDNESS AND URGENT ACTIONS
THURSDAY 2 JULY 2020 16:00-18:00 CET CONCLUSIONS
In “peace time”, significant investments are needed in:
• Non-pharmaceutical interventions (NPIs), protocols and necessary materials.
Vaccination
• Preparedness in primary care, nursing homes, hospitals and ICUs.
Ab Osterhaus, RIZ, Hannover , Germany • The scaling up of reliable diagnostic and surveillance capabilities.
Jonathan Anderson, Seqirus , Australia • Protocols for rapid clinical, virological and pathogenesis studies to help understand the virus
and the disease.
• Broadly protective vaccine platforms.
Antivirals • Broadly active antiviral platforms.
Frederick Hayden, University of Virginia , USA RECOMMENDATIONS
1. Prepare for a new COVID-19 wave.
Non-medical interventions 2. Introduce and comply with non-pharmaceutical interventions (e.g. physical distancing,
face masks, teleworking, school closures) as early as possible. The countries who introduced
Angeliki Melidou, ECDC , Sweden lockdown measures the earliest were the most effective.
3. Introduce infection prevention and control measures such as thorough Test, Track & Trace,
and Quarantine (TTTQ).
Cross-sector collaboration and communication
4. Establish more uniform NPI measures based on scientific evidence with the goal of achieving
Sylvie Briand, World Health Organisation , Switzerland consistency and homogeneous measures across the 28 EU countries and between continents.
5. Continue with vaccine development initiatives. Currently more than 200 COVID-19 initia-
tives are ongoing worldwide; 17 in humans.
6. Be realistic about promises of the potential of vaccine programmes against COVID-19.
7. Prepare for seasonal flu by developing a vaccination programme targeting a broad popula-
tion to limit the possible negative effect of two viruses appearing at the same time.
8. Develop antiviral options for treatment and prevention of influenza and COVID-19. Combina-
tions of antivirals can increase potency and decrease the risk of resistance emerging in influ-
enza and possibly also in COVID-19.
CORONAVIRUS,
FLU AND RSV
COLLIDING IN THE FALL
STATISTICS STATISTICS REPORT
AUDIENCE
REPORT
With a live attendance of 1.728 participants and 8.418 unique views
of the recordings we have reached a total audience of 10.146.
0 1.000 2.000 3.000 4.000 5.000 6.000 7.000 8.000 9.000 10.000
Attendees Unique views of the recordings
NUMBERS AT A GLANCE
■ 6 invitations and 4 take back home messages were sent to over 12.000 contacts.
■ More than 2.800 people participants registered from more than 95 different countries. COUNTRY TOP 10 CONCLUSIONS AND
95 different countries were present
RECOMMENDATIONS
during the webinars resulting in a top 10: The four webinars have resulted
■ USA in a two-pager containing
■ UK recommendations for clinicians
■ Saudi Arabia and policymakers. These have been
AFFILIATIONS ATTENDANCE RATE ■ Mexico disseminated through an extra
■ Belgium e-mail campaign on 9 July 2020, and
■ Germany on the eswiwebinar.org and eswi.
■ Netherlands org websites. The two-pager was
In total more than France
■
downloaded 1.916 times.
30% 33%
2.800 people ■
■
Romania
Russian Federation
registered for the webinars,
37% with a total of 1.728
live participants,
CAMPAIGN: TWITTER CAMPAIGN: FACEBOOK
Pharmaceutical Industry which is an 61,6%
In total we made 8 announcements good The 6 announcements were viewed 965
attendance rate. for 5.949 views and 400 interactions. times with 105 interactions.
Universities and clinicians
We tweeted 4 conclusions which were 4 conclusions were posted good for 507
Public Health Institutes and governments
viewed 2.591 times with 69 interactions. views and 65 interactions.
ESWI management would like to thank
The Organising Committee of the ESWI has been putting influenza pandemic
preparedness on the agenda of society for 3 decades
Seventh ESWI Influenza Conference now. Influenza and COVID-19 clearly have overlapping
was very excited to launch the Virtual pandemic preparedness strategies. Policy makers
edition of #ESWI2020. and scientists responsible for managing this raging
COVID-19 pandemic have turned to historical INFLUENZA
RSV DISEASE
We felt it is has never been more important to connect experience with influenza pandemics and for good
and come together with influenza, RSV disease, reason. Intervention strategies perspectives need to be
COVID-19 experts and policy makers. COVID-19 has addressed urgently and the clinical perspectives and
clearly shown that a previously unknown pathogen pathogenesis perspectives of influenza virus, RSV and
may strike at any time, in any place and without any SARS-CoV-2 need to be discussed between peers and
warning. There is a clear need for countries to have stakeholders.
the capacity to maintain effective alert and response
systems to detect and quickly react to outbreaks and We had hoped to reschedule the Seventh ESWI
to share information about such outbreaks rapidly and Influenza Conference “live version” later at the
transparently. beginning of December, but in September already
it became clear that large gatherings would still be
prohibited and existing travel bans would still be in
place, and additionally we wanted to prioritize the
health and safety of our faculty and attendees. We had
therefore decided to go ‘virtual’, and to make the 7th
ESWI Influenza Conference a virtual Conference.This was our programme:
THE SEVENTH ESWI INFLUENZA CONFERENCE #ESWI2020
THE SEVENTH ESWI INFLUENZA CONFERENCE #ESWI2020
THE SEVENTH ESWI INFLUENZA CONFERENCE #ESWI2020
THE SEVENTH ESWI INFLUENZA CONFERENCE #ESWI2020
THE SEVENTH ESWI INFLUENZA CONFERENCE #ESWI2020
THE SEVENTH ESWI INFLUENZA CONFERENCE #ESWI2020
Proceedings of the conference will be
Special Issue of Vaccine, Elsevier.
Separate report of the
Science Policy Interface
track is disseminated end
of December 2020 and
downloadable on the
influenzaconference.org site.STATISTICS / METRICS
PRE CONFERENCE DURING THE CONFERENCE
19 JULY 2020 – 5 DECEMBER 2020 6 DECEMBER – 9 DECEMBER 2020
79.944 pageviews in the conference platform
862 registrants
22 newsletters 90 tweets were sent with 94 mentions 64 different countries
were sent to a D-Base and 4.317 profile visits (interactions) 151
of 11.717 76 Facebook posts with abstract driven
members 10.465 interactions. oral presentations
176
Affiliations registrants posters
49.331 Pageviews of the Influenza Conference website Academics/Researchers 340
International agencies/
by 38.609 users Governments/
Federal Offices 160
1% Industry
Press
350
12
desktop
Total number of
mobile Science Sessions 15
tablet 13 %
Total number of
Science Policy 7
Interface sessions
Countries registrants Total number of
Satellite symposia 8
Total number of
86% Canada/USA/Mexico 154
Keynotes 16
Africa 10
Europe 522 Total number of
Australia/New Zealand 21 Webinars 4
South America 66
Asia 89 Total number of
Oral presentations 218
in all sessionsAFTER THE CONFERENCE
10 DECEMBER - STILL ONGOING
18.497 plays of sessions
TOP 20 videos
1. SCS: Epidemiology, surveillance and 11. SAT: Satellite symposium organised
modeling of influenza, RSV disease and by the Influenza Diabetes Community,
COVID-19, including virus evolution and supported by Sanofi Pasteur: Influenza
strain selection in persons living with diabetes.
Pathogenesis and prevention
2. Opening ceremony
12. SCS: Viral and host factors in the 9.489 people visited the public
1556
3. SPI: How to join forces in influenza pathogenesis of influenza, RSV disease
pandemic preparedness – what can we and COVID-19, including genomics and webpages during the conference
learn from COVID-19? big data
4. SCS: Webinar: Influenza and RSV in a
COVID-19 world
13. SCS: Influenza, RSV disease and
COVID-19 vaccination: current and
sessions views
future approaches 1. United 18. Turkey 36. Sri Lanka
5. SCS: Viral and host factors in the Kingdom 19. Argentina 37. Slovenia
transmission of influenza, RSV disease 14. SPI: Influenza, RSV disease and 2. United States
6585
20. Brazil 38. Hungary
and COVID-19, including genomics and COVID-19 intervention strategies:
big data current practice and future strategies
3. France 21. Hong Kong 39. Thailand
4. Netherlands 22. Norway 40. Lithuania
6. SCS: Virus structure and replication in 15. SAT: Satellite symposium organised
influenza virus, RSV and SARS-CoV-2;
latest developments in influenza virus,
by BioNTech: The Road to COVID-19
Vaccine Development
5.
6.
Belgium
Germany
23.
24.
Japan
Denmark
41.
42.
Costa Rica
Chile
page views
SARS-CoV-2 and RSV molecular virology
16. SAT: Satellite symposium organised by
7.
8.
Switzerland
Australia
25. Ukraine 43. El Salvador in the conference
7. SAT: Satellite symposium organised Janssen: Addressing the ever-changing 26. South Africa 44. Dominican
by Seqirus: Strengthening influenza
protection: Different needs, different
burden of RSV: The past, present and
post COVID-19
9.
10.
Spain
Finland
27. Canada
45.
Republic
Israel
platform
28. Korea
solutions 11. Sweden 46. Croatia
17. SCS: Reservoirs for future pandemics: 29. Brunei
8. SPI: All you need to know about threats from the animal world 12. Russian Darussalam 47. Mexico
influenza, RSV disease and COVID-19 Federation 30. Latvia 48. Oman
18. SCS: Webinar: Clinical manifestations of 13. Poland 31. Romania
9. SAT: Satellite symposium organised by Influenza, RSV and COVID-19
AstraZeneca: Targeting SARS-CoV-2: 14. Italy 32. Pakistan
Novel vaccines and antivirals for the 19. SCS: Late Breakers: novel and 15. Austria 33. Slovakia
prevention and treatment of COVID-19 outstanding scientific discoveries 16. China 34. Portugal
10. KEY: Keynote lecture: From SARS 20. KEY: Morning welcome lecture: Antiviral 17. Saudi Arabia 35. Kuwait
to COVID-19, understanding the and Immune Modifiers for Treatment of
interspecies transmission of SARS- Influenza, RSV and COVID-19
related coronaviruses4 - 7 DECEMBER 2021
SALZBURG, AUSTRIA
Preparation of the
8th ESWI Influenza Conference, SalzburgTOPICS • CALL FOR ABSTRACTS
The European Scientific
Working group on Influenza PANDEMICS FLU / COVID-19 EPIDEMIC INFLUENZA, RSV INTERVENTIONS INFLUENZA /
(ESWI) is looking forward ■ Early diagnostics and AND COVID-19 - AT RISK RSV AND COVID-19
epidemiology POPULATIONS ■ Rapid diagnostics (point of care
to organising the eighth ■ Patients with diabetes diagnostics, isolation policies,
■ Clinical manifestations (defining
edition of its ESWI Influenza risk groups, lessons from the last ■ Elderly infection prevention)
Conferences in Salzburg, pandemic) ■ Obesity ■ Antivirals and antibody therapies
Austria, on 12-15 December ■ Clinical interventions (including ■ Young children ■ Vaccination
antivirals, biological modifiers, ■ Travelers ■ Novel vaccination strategies
2021. In keeping with its immunomodulators)
■ Health care workers ■ Biological Response Modifiers
excellent scientific reputation, ■ Pre- pandemic and pandemic
■ Pre-infections ■ Symptomatic treatments (ECMO,
the upcoming eighth edition vaccines
■ Immunocompromised (disease/ clinical intervention strategies)
■ “Preparedness”: logistics,
will give the floor to the most drug/transplant) ■ Vaccine hesitancy
stockpiles, healthcare capacity,…
renowned influenza, RSV and ■ Differences in susceptibility
■ What is the evidence for risk
COVID-19 scientists, public between seasonal and pandemic (inclusion)
flu viruses ■ Mechanisms / factors that
health experts and healthcare increase susceptibility or disease
■ Threats and risk management of
professionals, discussing epidemics and pandemics severity
hot topics in epidemic and ■ Reservoirs for future pandemics:
pandemic flu, RSV and threats from the animal world
COVID-19. Preparing for the
next (flu) pandemic is high on
the agenda.
YOUNG SCIENTIST FUND ABOUT SALZBURG
Through the Young Scientist Fund, ESWI With a UNESCO-listed baroque old town, a high-on-a-hill
provides grants to young scientists to medieval fortress, galleries with phenomenal art, some
attend the Conference and to play an active of Europe’s finest concert halls and uplifting mountain
role in the programme – as speakers or views, Salzburg is a perfectly orchestrated Alpine city. In
as co-chairs of the sessions. Deadline for Winter, Salzburg twinkles with Christmas-market cheer
application: 6 September 2021. and world renowned orchestras play Mozart. Winter hiking
is especially enjoyable on the city mountains and free ski
shuttles take you from the city directly to the ski area.The fifth edition of the ESWI Young Both Dr. de Vries and Dr. Short gave
Scientist Best Body Of Work award a keynote lecture during the Young
was for Dr. Robert de Vries, Utrecht Scientists Plenary session at the
University, The Netherlands for his 7th ESWI Influenza Conference -
substantial accomplishments to date in #ESWI2020 virtual edition.
the field of understanding influenza virus
dynamics. Stimulating the careers of promising
researchers being one of ESWI’s
The first edition of the ESWI Young objectives, 50 Young Scientists have
Scientist Innovative Award, a research received a grant to the #ESWI2020 virtual
grant supported by Seqirus, was for edition – with the kind support of Seqirus.
Dr. Kirsty Short, University of All co-chairs of the scientific sessions
Queensland, Australia, for her innovative at the 2020 Conference were Young
research in vaccine development. Scientists.Influenza vaccination in children
ESWI has a long standing partnership with ESPID in order to put influenza childhood
vaccination high on the agenda of peers, clinicians and policy makers.
At the ESPID 2020 Virtual Meeting 26-29 October 2020, At the #ESWI2020 virtual edition, ESPID and ESWI organized a joint
ESPID and ESWI organized a joint symposium on symposium on 9 December 2020: Should we introduce national live
29 October 2020, 17:00-18:30 vaccination programmes for children?
This was the programme: This was the programme:
■ Introduction by Pieter Fraaij, The Netherlands ■ Why is influenza an important disease in children? An introduction
and Ab Osterhaus, Germany Terho Heikkinen, University of Turku, Finland (CHAIR)
■ Influenza virus transmission and children, ■ Efficacy and safety of seasonal influenza vaccination in children
Sander Herfst, The Netherland Ab Osterhaus, TiHo, Hannover, Germany
■ UK Pediatric Influenza Vaccine Programme, ■ The burden of paediatric influenza in the US: mortality,
Jemie Lopez Bernal, UK hospitalizations, outpatients visits and other outcome
■ Immunization: the vision for the coming decade, Patsy Stinchfield, Children’s Hospitals and Clinics of Minnesota, United
Katherine O’Brien, US States of America
■ Live Q&A with faculty and
■ How to increase vaccine confidence and counter parental doubts on
Terence Nolan, Australia and Antonios Aliprantis, US the safety and effectiveness of influenza vaccines?
Hanna Nohynek, Finnish Institute for Health and Welfare, Finland
■ Debate: should we introduce life vaccination programmes for
children?
Terho Heikkinen, University of Turku, FinlandInfluenza Diabetes Community
People with diabetes still face a higher In October 2017 leading diabetes organisations and ESWI
joined forces to forge an active Influenza/Diabetes community,
risk for influenza and its complications. implementing an action plan to better protect diabetes patients
National and international guidelines against the flu. To keep the momentum going the community
therefore advise that diabetes patients meets annually to investigate new opportunities for collaboration
and to continue raising awareness about the impact of influenza
be annually vaccinated against influenza. infection on diabetes patients.
The attention for the impact of influenza
on diabetes patients is, however, low and
so is the vaccine uptake in this group.
1. 2. 3. 4. 5.
Influenza is People with 3 to 6 times Higher rate Diabetes
a highly diabetes more likely of death is more
contagious have a to be difficult to
respiratory higher risk hospitalized manage
illness of getting
very ill
World Health Organization recommends
yearly influenza vaccination for high-risk patients,
including those with diabetes
www.influenzadiabetescommunity.orgLeading diabetes organisations and ESWI joined forces to forge an At the #ESWI2020 virtual edition, the IDC organized a symposium on
active Influenza/Diabetes community, implementing an action plan 9 December 2020 about “Influenza in persons living with diabetes:
to better protect diabetes patients against the flu. The community pathogenesis and prevention.
meets annually to investigate new opportunities for collaboration
and to continue raising awareness about the impact of influenza This was the programme:
infection on diabetes patients.
PROGRAMME:
Current Influenza/Diabetes community members are: ■ The impact of influenza on people with diabetes
Marco Goeijenbier, Erasmus MC, The Netherlands (CHAIR)
■ The International Diabetes Federation (IDF Europe)
■ Influenza vaccination and people with diabetes: a must !
■ Foundation of European Nurses in Diabetes (FEND) Francesc Xavier Cos, Primary Care Diabetes Europe/ Institut Català de la
■ Pharmacist Group to the European Union (PGEU) salut, Spain (CHAIR)
■ Diabetes UK ■ Recent findings in glycemic variability and influenza severity
■ Primary Care Diabetes Europe (PCDE) Kirsty Short, University of Queensland, Australia
■ Immunology of Diabetes Society (IDS) ■ How to increase vaccination coverage in people with diabetes,
■ European Association for the Study of Diabetes (EASD) the UK case
■ Nurse Practitioner Healthcare Foundation (NPHF) Dan Howarth, Diabetes UK, United Kingdom
■ American Association of Diabetes Educators (AADE) ■ Diabetes during the COVID-19 pandemic
■ American Pharmacists Association (APhA) Ab Osterhaus, TiHo, Hannover, Germany
■ International Federation of Ageing (IFA)
PGEU GPUE
Pharmaceutical Group of the European Union
Groupement Pharmaceutique de L’Union Européenne
A web portal was created to serve as
a virtual reference centre on diabetes
and influenza, containing web materials
of ESWI’s partners in the
Influenza Diabetes community on diabetes
and on the importance of flu vaccines.
www.influenzadiabetescommunity.orgCommunication tools
SOCIAL MEDIA STRATEGY ESWI WEB PORTAL
ESWI continues to create, collect and Visitors of the www.eswi.org portal website The ESWI portal website also hosts the
disseminate relevant scientific content can browse through our videos on various Influenza/Diabetes community webpages,
about influenza with three important influenza topics in ESWI TV, get the a dedicated influenza/diabetes section
objectives: information they need from our influenza that serves as a virtual reference center on
■ to reinforce ESWI’s reputation and knowledge center, stay informed about diabetes and influenza.
increase “brand” awareness ESWI’s biennial influenza conferences, its
■ to increase interaction with target symposia and roundtables, and the yearly www.influenzadiabetescommunity.org
audiences Influenza Summits.
■ to promote ESWI events and increase
the number of attendees ESWI is determined to expand and update
the content on the portal in order to
maintain relevance and authority.
www.eswi.orgCommunication tools ESWI NEWSLETTER - FLUZINE ESWI manages and constantly updates a database of some 15,000 influenza stakeholders worldwide. ESWI is ready to use this platform in any influenza- related educational project, as it is a highly flexible tool to reach the global flu field in just a few clicks. Another tool in ESWI’s web-based communication strategy is its monthly newsletter. The ESWI newsletter FLUZINE offers a selection of influenza- related articles collected from a range of media sources. Fluzine is hence a cost- effective way to enhance ESWI’s visibility in the influenza community.
2021 will again be an interesting, busy and fascinating year for ESWI. To realize its aims, however, ESWI fully relies on the loyal and active support of its members, partner organisations and sponsoring companies. Their joint forces are the strength of ESWI, allowing the organisation to play its unique role in the influenza field. If you have any questions about the European Scientific Working group on Influenza, please contact info@eswi.org
You can also read
